Phase 2, Phase 3 Recruiting Academic/Other
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Sponsor: NRG Oncology
NCT ID: NCT05174169
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Thomas Hospital — Fairhope, Alabama
- Mobile Infirmary Medical Center — Mobile, Alabama
+ 1020 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Locations: - Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
- Alaska Oncology and Hematology LLC — Anchorage, Alaska
+ 373 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Locations: - Kingman Regional Medical Center — Kingman, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Tower Cancer Research Foundation — Beverly Hills, California
+ 182 more sites in the U.S.
Phase 3 Recruiting Industry
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participa…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05253651
Locations: - Palo Verde Hematology Oncology — Glendale, Arizona
- Mayo Clinic Building - Phoenix — Phoenix, Arizona
- Mayo Clinic Hospital — Phoenix, Arizona
+ 125 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
Sponsor: Incyte Corporation
NCT ID: NCT07284849
Locations: - Ironwood Cancer & Research Centers — Chandler, Arizona
- The University of Arizona Cancer Center — Tucson, Arizona
- Roche Tissue Diagnostics, Companion Diagnostics — Tucson, Arizona
+ 77 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Banner-University Medical Center Phoenix — Phoenix, Arizona
+ 57 more sites in the U.S.
Phase 3 Recruiting Industry
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevaci…
Sponsor: Amgen
NCT ID: NCT06252649
Locations: - Ironwood Cancer and Research Centers Scottsdale — Chandler, Arizona
- Providence Saint Jude Medical Center — Fullerton, California
- City of Hope National Medical Center — Long Beach, California
+ 23 more sites in the U.S.
Phase 3 Recruiting Industry
The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.
Sponsor: Surgimab
NCT ID: NCT03659448
Locations: - City of Hope National Medical Center — Duarte, California
- Moores Cancer Center - UCSD Health — La Jolla, California
- Cleveland Clinic Florida — Weston, Florida
+ 3 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility therapeutic trial. The study will enroll 20 patients across 4 cohorts (CRC, gastric, PDAC, and HCC/intra-hepatic-/extra-hepatic-, gall bladder adenocar…
Sponsor: Georgetown University
NCT ID: NCT05482516
Locations: - Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
- Medstar Washington Hospital Center — Washington D.C., District of Columbia
- John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
Phase 3 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard…
Sponsor: AbbVie
NCT ID: NCT07525206
Locations: - Astera Cancer Care /ID# 279532 — East Brunswick, New Jersey
Phase 3 Recruiting Academic/Other
This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (…
Sponsor: Roswell Park Cancer Institute
NCT ID: NCT06563388
Locations: - Roswell Park Comprehensive Cancer Center — Buffalo, New York
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Locations: - University of Alabama at Birmingham — Birmingham, Alabama
- Mayo Clinic (Arizona) — Scottsdale, Arizona
- University of Arkansas - Winthrop P. Rockefeller Cancer Institute — Little Rock, Arkansas
+ 37 more sites in the U.S.